EEG | - Interictal: Abnormal with slowing and focal/multifocal discharges or burst suppression pattern
| | |
Neurologic examination | | - Lack of encephalopathy and irritability
| |
Other testing (eg, genetics) | - Laboratory testing providing confirmatory evidence, which may include:
- Metabolic features: Increased alpha-aminoadipic semialdehyde and/or pipecolic acid in urine, plasma, and/or CSF (pyridoxine-dependent-DEE) or low pyridoxal-5-phosphate in CSF (pyridox(am)ine 5'-phosphate-DEE)
- Genetic features: Pathogenic variants in ALDH7A1 or PLBP (pyridoxine dependent-DEE) or PNPO gene (pyridox(am)ine 5'-phosphate-DEE)
| | |
Course of illness | - Seizures that show sustained marked reduction or cessation with lifelong pyridoxine or pyridoxal-5-phosphate
| - Normal neurodevelopmental outcome
| |
Syndrome without laboratory confirmation: In resource-limited regions, pyridoxine or pyridox(am)ine 5'-phosphate-DEE can be diagnosed in children without alerts who meet all other mandatory and exclusionary clinical criteria and whose seizures cease with pyridoxine or P5P supplementation, recur when supplementation is stopped, and cease again with reintroduction of supplementation |